Aromatase inactivation by 2-substituted derivatives of the suicide substrate androsta-1,4-diene-3,17-dione

Journal of Steroid Biochemistry and Molecular Biology

Volumn 116, Issue 3-5, 2009, Pages 191-199

  Takahashi, Madoka ^a   Handa, Wakako ^a   Umeta, Hiromi ^a   Ishikawa, Saki ^a   Yamashita, Kouwa ^a   Numazawa, Mitsuteru ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

2 Alkoxyandrosta 1,4 diene 3,17 dione; 2 Alkylandrosta 1,4 diene 3,17 dione; Aromatase inhibitor; Estrogen dependent breast cancer; Human placental microsomes; Structure activity relationship; Suicide substrate

Indexed keywords

2 ALKOXYANDROSTA 1,4 DIENE 3,17 DIONE DERIVATIVE; 2 ALKYLANDROSTA 1,4 DIENE 3,17 DIONE DERIVATIVE; 2 BROMO 17BETA ACETOXYANDROSTA 1,4 DIEN 3 ONE; 2 BROMO 17BETA HYDROXYANDROSTA 1,4 DIEN 3 ONE; 2 BROMOANDROSTA 1,4 DIEN 3 ONE; 2 ETHYLANDROSTA 1,4 DIENE 3,17 DIONE; 2 HYDROXYANDROSTA 1,4 DIENE 3,17 DIONE; 2,4ALPHA DIBROMO 17BETA ACETOXY 5ALPHA ANDROST 1 EN 3 ONE; 2ALPHA ALKYL 17BETA HYDROXYANDROST 4 EN 3 ONE DERIVATIVE; 2ALPHA ALKYL 17BETA TERT BUTYLDIMETHYLSILOXYANDROST 4 EN 3 ONE DERIVATIVE; 2ALPHA ALKYLANDROST 4 ENE 3,17 DIONE DERIVATIVE; ANDROSTA 1,4 DIENE 3,17 DIONE DERIVATIVE; ANDROSTENEDIONE DERIVATIVE; AROMATASE; AROMATASE INHIBITOR; CYSTEINE; SUICIDE SUBSTRATE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MICROSOME; PHARMACOLOGICAL BLOCKING; PLACENTA; STRUCTURE ACTIVITY RELATION;

ANDROSTADIENES; AROMATASE; AROMATASE INHIBITORS; FEMALE; HUMANS; MICROSOMES; PLACENTA; PREGNANCY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67650659854     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2009.05.015     Document Type: Article

References (49)

1. Thompson Jr. E.A., and Siiteri P.K. The involvement of human placental microsomal cytochrome P-450 in aromatization. J. Biol. Chem. 249 (1974) 5373-5378
2. Kellis Jr. J.T., and Vickery L.E. Purification and characterization of human placental aromatase cytochrome P-450. J. Biol. Chem. 262 (1987) 4413-4420
3. Yoshida N., and Osawa Y. Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization. Biochemistry 30 (1991) 3003-3010
4. Thompson Jr. E.A., and Siiteri P.K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 249 (1974) 5364-5372
5. 4-androstene-3,17-dione to estrone by endocrine tissue. Biochem. Biophys. Acta 17 (1955) 441-442
6. 4-androstene-3,17-dione by placental microsomes. Endocrinology 71 (1962) 723-728
7. Skinner S.J., and Akhtar M. The stereospecific removal of a C-19 hydrogen atom in oestrogen biosynthesis. Biochem. J. 114 (1969) 75-81
8. Akhtar M., Calder M.R., Corina D.L., and Wright J.N. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. Biochem. J. 201 (1982) 569-580
9. Covey D.F. Aromatase inhibitors: specific inhibitors of estrogen biosynthesis. In: Berg D., and Plempel M. (Eds). Sterol Biosynthesis Inhibitors: Pharmaceutical and Agrochemical Aspects (1988), Eliss Horwood Ltd, Chichester 534-571
10. Oh S.S., and Robinson C.H. Mechanism of human placental aromatase: a new active site model. J. Steroid Biochem. Mol. Biol. 44 (1993) 389-397
11. Akhtar M., Lee-Robichaud P., Akhtar M.E., and Wright J.N. The impact of aromatase mechanism on other P450 s. J. Steroid Biochem. Mol. Biol. 61 (1997) 127-132
12. 2H]androgens into oestrogens by human placental aromatase. An unexpected stereochemical outcome. Biochem. J. 268 (1990) 553-561
13. 2. J. Chem. Soc. Chem. Commun. (1976) 854-856
14. Cole P.A., and Robinson C.H. Peroxide model reaction for placental aromatase. J. Am. Chem. Soc. 110 (1988) 1284-1285
15. Vanden Bossche H. Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment. J. Steroid Biochem. Mol. Biol. 43 (1992) 1003-1021
16. Brodie A.M., and Santen R.J. Aromatase and its inhibitors in breast cancer treatment-overview and perspective. Breast Cancer Res. Treat. 30 (1994) 1-6
17. Johnston J.O. Aromatase inhibitors. Crit. Rev. Biochem. Mol. Biol. 33 (1998) 375-405
18. Harper-Wynne C., and Dowsett M. Recent advances in the clinical application of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 76 (2001) 179-186
19. Ryan K.J. Biological aromatization of steroids. J. Biol. Chem. 234 (1959) 268-272
20. Gual C., Morato T., Hayano M., Gut M., and Dorfman R.I. Biosynthesis of estrogens. Endocrinology 71 (1962) 920-925
21. Meigs R.A., and Ryan K.J. Enzymatic aromatization of steroids. I. Effects of oxygen and carbon monoxide on the intermediate steps of estrogen biosynthesis. J. Biol. Chem. 246 (1971) 83-87
22. Milewich L., Bradfield D.J., Coe L.D., Masters B.S.S., and MacDonald P. Metabolism of 1,4-androstadiene-3,17-dione by human placental microsomes. Enzyme properties and kinetic parameters in the formation of estrogens and 17β-hydroxy-1,4-androstadien-3-one. J. Steroid Biochem. 14 (1981) 1115-1125
23. Numazawa M., Yoshimura A., and Oshibe M. Enzymic aromatization of 6-alkyl-substituted androgens, potent competitive and mechanism-based inhibitors of aromatase. Biochem. J. 329 (1998) 151-156
24. 1,4,6-androgens and their 6-alkyl analogs, potent inhibitors of aromatase. J. Steroid Biochem. Mol. Biol. 70 (1999) 189-196
25. Schwarzel W.C., Kruggel W.G., and Brodie H.J. Studies on the mechanism of estrogen biosynthesis. VIII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92 (1973) 866-880
26. Covey D.F., and Hood W.F. Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 108 (1981) 1597-1599
27. Covey D.F., and Hood W.F. A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase. Cancer Res. 42 Suppl. (1982) 3327s-3333s
28. Marsh D.A., Brodie H.J., Garrett W., Tsai-Morris C.H., and Brodie A.M.H. Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives. J. Med. Chem. 28 (1985) 788-795
29. 1-testololactone on clinical course and hormonal excretion. Cancer 13 (1960) 1017-1020
30. 1-Testololactone, a nonadrogenic augmentor and inhibitor of androgens. Cancer 13 (1960) 1201-1205
31. Henderson D., Norbisrath G., and Kerb U. 1-Methyl-1,4-androstadiene-3,17-dione (SH 489): characterization of an irreversible inhibitor of estrogen biosynthesis. J. Steroid Biochem. 24 (1986) 303-306
32. Di Salle E., Briatico G., Giudici D., Ornati G., and Zaccheo T. Aromatase inhibition and experimental antitumor activity of FCE 24304, MDL 18962 and SH 489. J. Steroid Biochem. 34 (1989) 431-434
33. Di Salle E., Ornati G., Giudici D., Lassus M., Evans R.J., and Coombes R.C. Exemestane (FCE 24304). A new steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 43 (1992) 137-143
34. Numazawa M., Oshibe M., Yamaguchi S., and Tachibana M. Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group. J. Med. Chem. 39 (1996) 1033-1038
35. 19 steroids having a 1,4-diene,4,6-diene, or 1,4,6-triene structure as aromatase inhibitors. Steroids 64 (1999) 187-196
36. Numazawa M., Shelangouski M., and Nagasaka M. Probing the binding pocket of the active site of aromatase with 6-ether or 6-ester substituted androst-4-ene-3,17-diones and their diene and triene analogs. Steroids 65 (2000) 871-882
37. Numazawa M., Nagaoka M., Handa W., Ogawa Y., and Matsuoka S. Studies directed towards a mechanistic evaluation of inactivation of aromatase by the suicide substrates androta-1,4-diene-3,17-diones and its 6-ene derivatives. Aromatase inactivation by the 19-substituted derivatives and their enzymic aromatization. J. Steroid Biochem. Mol. Biol. 107 (2007) 211-219
38. Numazawa M., Handa W., and Yamada K. Synthesis and biochemical properties of 6-bromoandrostenedione derivatives with a 2,2-dimethyl or 2-methyl group as aromatase inhibitors. Biol. Pharm. Bull. 27 (2004) 1878-1882
39. Burnett R.D., and Kirk D. Some observations on the preparation of 2-hydroxy-steroid 2-en-3-ones. J. Chem. Soc. Perkin Trans. 1 (1973) 1830-1836
40. Hosoda H., Yamashita K., Sagae H., and Nambara T. Steroids. CI. Dimethyl-tert-butylsilyl ethers of steroids. Chem. Pharm. Bull. 23 (1975) 2118-2122
41. Counsell R.E., and Klimstra P.D. Anabolic agents: derivatives of 2-halo-5α-androst-1-ene. J. Med. Pharm. Chem. 5 (1962) 477-483
42. Numazawa M., Handa W., Hasegawa C., and Takahashi M. Structure-activity relationships of 2α-substituted androstenedione analogs as aromatase inhibitors and their aromatization reactions. J. Steroid Biochem. Mol. Biol. 97 (2005) 353-359
43. Nedelec L., Gasc J.C., and Bucourt R. The kinetically controlled methylation of conjugated polycyclic ketones. Tetrahedron 30 (1974) 3263-3268
44. Djerassi C., and Scholz C.R. Preparation and dienone-phenol rearrangement of 2-bromo-1,4-androstadien-17-ol-3-one 17-hexahydrobenzoate. JACS 70 (1948) 1911-1913
45. Siiteri P.K., and Thompson E.A. Human placental aromatase. J. Steroid Biochem. 6 (1975) 317-322
46. Kitz R., and Wilson I.B. Effects of metanesulfonic acid as irreversible inhibitors of acetylcholine esterase. J. Biol. Chem. 237 (1962) 3245-3249
47. Silverman R.B. Mechanism-based Enzyme Inactivation vol. 1 (1988), CRC Press, Boca Raton, FL pp. 3-30 (Chapter 1)
48. Johnson J.O., and Metcalf B.W. Aromatase: a target enzyme in breast cancer. In: Sunkara P.S. (Ed). Novel Approaches to Cancer Chemotherapy (1984), Academic Press, New York 307
49. Ghosh D., Griswold J., Erman M., and Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 457 (2009) 219-223